StockMacro
Menu

Humacyte

$0.45 -60% in 6 monthsMarket cap $123.7M

HUMA on XNAS, Health Care, Humacyte, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 53% but the company lost $94.8M while the stock fell 60% in a year.

  • BadShort interest 10% of shares, 7.2 days to cover

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
184
Website
humacyte.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 18 Mar 2027 (an estimate: a year ago it reported on 19 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.0M, net loss $15.5M.
Quarter to 31 Dec 2021: revenue –, net income $42.6MQuarter to 31 Mar 2022: revenue –, net income -$19.8MQuarter to 30 Jun 2022: revenue –, net income $36.9MQuarter to 30 Sep 2022: revenue –, net income -$25.3MQuarter to 31 Dec 2022: revenue –, net income -$3.7MQuarter to 31 Mar 2023: revenue –, net income -$37.0MQuarter to 30 Jun 2023: revenue –, net income -$22.7MQuarter to 30 Sep 2023: revenue –, net income -$26.0MQuarter to 31 Dec 2023: revenue –, net income -$25.1MQuarter to 31 Mar 2024: revenue $0, net income -$31.9MQuarter to 31 Mar 2024: revenue $0, net income -$31.9MQuarter to 30 Jun 2024: revenue $0, net income -$56.7MQuarter to 30 Jun 2024: revenue $0, net income -$56.7MQuarter to 30 Sep 2024: revenue $0, net income -$39.2MQuarter to 30 Sep 2024: revenue $0, net income -$39.2MQuarter to 31 Dec 2024: revenue $0, net income -$20.9MQuarter to 31 Dec 2024: revenue $0, net income -$20.9MQuarter to 31 Mar 2025: revenue $517K, net income $39.1MQuarter to 31 Mar 2025: revenue $517K, net income $39.1MQuarter to 30 Jun 2025: revenue $301K, net income -$37.7MQuarter to 30 Jun 2025: revenue $301K, net income -$37.7MQuarter to 30 Sep 2025: revenue $753K, net income -$17.5MQuarter to 30 Sep 2025: revenue $753K, net income -$17.5MQuarter to 31 Dec 2025: revenue $467K, net income -$24.8MQuarter to 31 Dec 2025: revenue $467K, net income -$24.8MQuarter to 31 Mar 2026: revenue $495K, net income -$17.6MQuarter to 31 Mar 2026: revenue $495K, net income -$17.6MQuarter to 30 Jun 2026: revenue $406K, net income -$36.8MQuarter to 30 Jun 2026: revenue $406K, net income -$36.8MQuarter to 30 Sep 2026: revenue $1.0M, net income -$15.5MQuarter to 30 Sep 2026: revenue $1.0M, net income -$15.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $56.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.0M-$15.5M
30 Jun 2026$406K-$36.8M
31 Mar 2026$495K-$17.6M
31 Dec 2025$467K-$24.8M
30 Sep 2025$753K-$17.5M
30 Jun 2025$301K-$37.7M
31 Mar 2025$517K$39.1M
31 Dec 2024$0-$20.9M
30 Sep 2024$0-$39.2M
30 Jun 2024$0-$56.7M
31 Mar 2024$0-$31.9M
31 Dec 2023–-$25.1M
30 Sep 2023–-$26.0M
30 Jun 2023–-$22.7M
31 Mar 2023–-$37.0M
31 Dec 2022–-$3.7M
30 Sep 2022–-$25.3M
30 Jun 2022–$36.9M
31 Mar 2022–-$19.8M
31 Dec 2021–$42.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.4M $1.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +53% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$94.8M -$37.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.46 -$0.23
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. -475% 60.5% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $64.5M $19.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $36.8M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$27.7M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 2.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.07
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 51.6 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 40.1 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.8 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
HumacyteHUMA (this company) $123.7Mloss51.6+53%–
Compass TherapeuticsCMPX $123.9Mloss–––
InvivydIVVD $122.0Mloss2.0+21%-215%
enGene TherapeuticsENGN $116.6Mloss–––
Armata PharmaceuticalsARMP $112.7Mloss–––
Fate TherapeuticsFATE $111.8Mloss23.5-33%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$6K

bought $6K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-18%

129 13F filers vs 158

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

20%

54.5M shares held by 13F filers (30 Sep 2026) of 277.8M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

10%

28.1M shares sold short (30 Oct 2026) of 277.8M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.2

28.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-7.2%

30.3M shares sold short in the report before, 28.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

14

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$200K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.0×

8 articles in the last 7 days; its usual week has 2.

Price $0.45 on 20 Nov 2026, -60% over 12 months (12-month range $0.35 to $1.49)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $7K in the last 12 months (the 12 months before: -$3.6M).
Revenue per quarter. Revenue $1.0M in the latest quarter, +37% on a year earlier.
Capital spending per quarter. Capital spending $104K in the latest quarter.
Institutional holders (13F filers). 129 13F filers reported holding it in the latest 13F quarter, -3.7% on a year earlier.
Lobbying spend. Lobbying spend: $200K published in the last 12 months, +122% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
28 Sep 20268-K and other filingsDirector or officer change
28 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Jul 20268-K and other filingsDelisting notice or listing transfer
8 May 20268-K and other filingsDelisting notice or listing transfer
15 Dec 20258-K and other filingsA major agreement ended
26 Nov 20258-K and other filingsA major agreement ended
20 Oct 2025Lobbying filingnew lobbying registration (CAPITOL HILL CONSULTING GROUP)
15 Oct 2025Lobbying filinglobbying engagement terminated (G2G CONSULTING)
21 Apr 2025Lobbying filinglobbying engagement terminated (DLA PIPER LLP (US))
15 Apr 2025Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 5 filing(s) in 30 days, value_usd total 136K)
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 34 vs usual 12.50 (2024-12-31); 4.2x the same period a year earlier
14 Jan 2025Sharp changeShort interest spike: short interest spike, 29.6M vs usual 7.4M (2024-12-31); 4.9x the same period a year earlier
31 Dec 2024Sharp changeShort interest spike: short interest spike, 22.0M vs usual 6.3M (2024-12-13); 3.9x the same period a year earlier
17 Dec 2024Sharp changeShort interest spike: short interest spike, 20.3M vs usual 6.1M (2024-11-29); 3.5x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 19.1M vs usual 6.1M (2024-11-15); 3.1x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 17.3M vs usual 6.1M (2024-10-31); 3.1x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 32 vs usual 10.50 (2024-09-30); 2.3x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 16.7M vs usual 6.0M (2024-10-15); 3.3x the same period a year earlier
21 Oct 2024Sharp changeLobbying on a new issue: lobbying on a new issue: BUD (2024-09-30)
15 Oct 2024Sharp changeShort interest spike: short interest spike, 16.0M vs usual 5.9M (2024-09-30); 3.0x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 14.0M vs usual 5.7M (2024-09-13); 2.7x the same period a year earlier
26 Sep 2024Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
17 Sep 2024Sharp changeShort interest spike: short interest spike, 11.3M vs usual 5.5M (2024-08-30); 3.0x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 11.4M vs usual 5.4M (2024-08-15); 3.6x the same period a year earlier
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 40 vs usual 10.50 (2024-06-30); 3.6x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 12.0M vs usual 5.3M (2024-07-31); 4.0x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 14.6M vs usual 5.2M (2024-07-15); 4.9x the same period a year earlier
13 Jun 20248-K and other filingsDirector or officer change
13 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Jun 2024Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 748K)
8 Feb 2024Lobbying filingnew lobbying registration (G2G CONSULTING)
20 Oct 2023Lobbying filinglobbying engagement terminated (FEDERAL HEALTH POLICY STRATEGIES)
20 Apr 2023Sharp changeLobbying on a new issue: lobbying on a new issue: HCR (2023-03-31)
17 Apr 2023Lobbying filingnew lobbying registration (FEDERAL HEALTH POLICY STRATEGIES)
20 Dec 2022Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 118K)
20 Sep 20228-K and other filingsDirector or officer change
20 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Sep 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 481K)
26 May 2022Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 5 filing(s) in 30 days, value_usd total 165K)
27 Dec 20218-K and other filingsDirector or officer change
27 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: $27K published
Month from 1 Dec 2021: -$5.5M published
Month from 1 May 2022: $165K published
Month from 1 Sep 2022: -$11.7M published
Month from 1 Dec 2022: -$5.0M published
Month from 1 May 2023: -$14.5M published
Month from 1 Jun 2023: -$28.5M published
Month from 1 Aug 2023: -$12.8M published
Month from 1 Sep 2023: -$5.6M published
Month from 1 May 2024: $718K published
Month from 1 Jun 2024: -$13.9M published
Month from 1 Aug 2024: -$6.0M published
Month from 1 Sep 2024: -$2.4M published
Month from 1 Nov 2024: -$6.6M published
Month from 1 Dec 2024: $20K published
Month from 1 Apr 2025: $146K published
Month from 1 Aug 2025: -$3.7M published
Month from 1 May 2026: -$23K published
Month from 1 Aug 2026: $25K published
Month from 1 Sep 2026: $6K published
Revenue per quarter
Quarter ended 31 Mar 2024: $0; public on 14 May 2025
Quarter ended 30 Jun 2024: $0; public on 12 Aug 2025
Quarter ended 30 Sep 2024: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2024: $0; public on 28 Mar 2026
Quarter ended 31 Mar 2025: $517K; public on 14 May 2025
Quarter ended 30 Jun 2025: $301K; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $753K; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $467K; public on 28 Mar 2026
Quarter ended 31 Mar 2026: $495K, -4.3% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $406K, +35% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $1.0M, +37% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $13K; public on 30 Mar 2022
Quarter ended 31 Mar 2021: $29K; public on 14 May 2022
Quarter ended 30 Jun 2021: $63K; public on 13 Aug 2022
Quarter ended 31 Dec 2021: $45K, +246% on a year earlier; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $22K, -24% on a year earlier; public on 14 May 2022
Quarter ended 30 Jun 2022: $134K, +113% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $211K, +154% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $681K, +1413% on a year earlier; public on 25 Mar 2023
Quarter ended 31 Mar 2023: $1.2M, +5136% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $485K, +262% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $493K, +134% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $150K, -78% on a year earlier; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $391K, -66% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $184K, -62% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $934K, +89% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $63K, -58% on a year earlier; public on 1 Apr 2025
Quarter ended 31 Mar 2025: $228K, -42% on a year earlier; public on 14 May 2025
Quarter ended 30 Sep 2025: $49K, -95% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $39K, -38% on a year earlier; public on 28 Mar 2026
Quarter ended 31 Mar 2026: $175K, -23% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $104K; public on 13 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 54; public on 14 Feb 2022
31 Mar 2022 report: 69; public on 16 May 2022
30 Jun 2022 report: 75; public on 15 Aug 2022
30 Sep 2022 report: 67; public on 14 Nov 2022
31 Dec 2022 report: 69; public on 14 Feb 2023
31 Mar 2023 report: 67; public on 15 May 2023
30 Jun 2023 report: 69; public on 14 Aug 2023
30 Sep 2023 report: 76; public on 14 Nov 2023
31 Dec 2023 report: 83; public on 14 Feb 2024
31 Mar 2024 report: 91; public on 15 May 2024
30 Jun 2024 report: 118; public on 14 Aug 2024
30 Sep 2024 report: 137; public on 14 Nov 2024
31 Dec 2024 report: 161; public on 14 Feb 2025
31 Mar 2025 report: 165; public on 15 May 2025
30 Jun 2025 report: 151; public on 14 Aug 2025
30 Sep 2025 report: 134; public on 14 Nov 2025
31 Dec 2025 report: 140; public on 17 Feb 2026
31 Mar 2026 report: 154; public on 15 May 2026
30 Jun 2026 report: 158; public on 14 Aug 2026
30 Sep 2026 report: 129; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2023: $10K published
Quarter from 1 Apr 2024: $10K published
Quarter from 1 Jul 2024: $10K published
Quarter from 1 Oct 2024: $20K published
Quarter from 1 Jan 2025: $20K published
Quarter from 1 Apr 2025: $10K published
Quarter from 1 Jul 2025: $10K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $50K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F funds opening a position at 11 (30 Sep 2026), 64% below its normal reading of 30.5; higher than 29% of its own history.
  • Insider net buying (open market): Insiders bought a net $7K in the last 12 months (the 12 months before: -$3.6M).
  • Revenue per quarter: Revenue $1.0M in the latest quarter, +37% on a year earlier.
  • Capital spending per quarter: Capital spending $104K in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 84 insider trades

Last 90 days: no sales; 1 purchase, $6K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
15 Sep 2026Keith Anthony JonesDirectorBuy10,000$0.56$6KForm 4
21 Aug 2026Keith Anthony JonesDirectorBuy10,000$0.69$7KForm 4
19 Aug 2026Keith Anthony JonesDirectorBuy30,000$0.59$18KForm 4
20 May 2026Shamik J ParikhChief Medical OfficerSellplanned in advance (10b5-1)45,887$0.90$41KForm 4
20 May 2026Dale A. SanderCFO and Chief Corp. Dev. OffSellplanned in advance (10b5-1)45,887$0.90$41KForm 4
20 May 2026Kathleen SebeliusDirectorBuy56,818$0.88$50KForm 4
20 May 2026Michael T. ConstantinoDirectorBuy11,000$0.89$10KForm 4
20 Aug 2025Laura E NiklasonPresident, CEO and DirectorSell2,241,045$1.67$3.7MForm 4

129 institutions reported shares at the end of Q3 2026, 20% of the shares outstanding; 11 opened a position, 40 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Vanguard Capital Management LLC11.0M3.95%$5.7M+856K+8.5%
ANTIPODES PARTNERS Ltd8.3M2.97%$4.3M-1.8M-18%
BlackRock, Inc.4.6M1.64%$2.4M-274K-5.7%
Great Point Partners LLC3.8M1.35%$1.9MNo change
UBS Group AG3.0M1.08%$1.6M+164K+5.8%
Marshall Wace, LLP3.0M1.08%$1.6M+2.8M16 times as many
Geode Capital Management, LLC2.7M0.96%$1.4M+491K+22%
Citadel Advisors LLC1.7M0.62%$897K+290K+20%
Susquehanna International Group, LLP1.7M0.60%$865K-29K-1.7%
Vanguard Fiduciary Trust Co1.6M0.58%$829K+418K+35%

Company events

All 33 company events

In 12 months: 5 major agreements, 2 agreements ended, 2 delisting notices, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Sep 2026Director or officer change8-K
31 Jul 2026Delisting notice or listing transfer8-K
11 Jun 2026Signed a major agreement8-K
8 May 2026Delisting notice or listing transfer8-K
24 Apr 2026Signed a major agreement8-K
19 Mar 2026Signed a major agreement8-K
16 Dec 2025Signed a major agreement8-K
15 Dec 2025A major agreement ended8-K

14 open postings; careers site tracked since 21 Nov 2026. Most in Legal, policy & compliance 14%, Process engineering (semiconductor / materials) 14%, Finance & accounting 7%, Mechanical engineering 7%.

PostedJobLocation
17 Nov 2026Quality Assurance SpecialistFinance & accountingNorth Carolina, Durham, NC, US
17 Nov 2026Senior Electrical TechnicianNorth Carolina, Durham, NC, US
11 Nov 20262D Bioprocessing Associate IINorth Carolina, Durham, NC, US
11 Nov 20262D Bioprocessing Associate INorth Carolina, Durham, NC, US
10 Nov 2026Warehouse Logistics Associate ISupply chain & procurementNorth Carolina, Durham, NC, US
6 Nov 2026Sr. Dir., Regulatory & Assc. General CounselLegal, policy & complianceRemote, US
4 Nov 2026MSAT Engineer IINorth Carolina, Durham, NC, US
2 Nov 2026Director, Regulatory AffairsLegal, policy & complianceNorth Carolina, Durham, NC, US; Remote, US

Reported lobbying spend: $50K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Aug 2025EndedG2G Consultingfor HumacyteTrauma careHealth issuesFiling
15 Jul 2025NewCapitol Hill Consulting Groupfor HumacytePayment for approved medical devices.Health issues, Medicare/Medicaid, DefenseFiling
1 Jan 2025EndedDla Piper LLP (US)for Humacyte, Inc.Not statedFiling
1 Sep 2024NewDla Piper LLP (US)for Humacyte, Inc.Policies and proposals related to FY25 appropriations and National Defense Authorization Act supportive language.BudgetFiling
1 Feb 2024NewG2G Consultingfor HumacyteRegarding awareness of and funding for biotechnologyHealth issuesFiling
30 Jun 2023EndedFederal Health Policy Strategiesfor HumacyteNot statedFiling
15 Mar 2023NewFederal Health Policy Strategiesfor HumacyteAccess to and reimbursement for innovative regenerative medicine therapiesMedicare/Medicaid, Health issuesFiling
1 Aug 2021EndedLincoln Policy Groupfor Humacyte, Inc.Access to regenerative medical technologies.Medicare/MedicaidFiling

The 5 newest of 124 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

20 Aug 2024confirmed

Confirmed across sources Institutional holdings and Lobbying and Short interest and volume

Humacyte (HUMA): saw 40 13F filers open a new position in the quarter ended 30 Jun 2024, 3.6× the same quarter last year; it also had 14.0M shares sold short in the 13 Sep 2024 report, 2.7× the same report last year; and it lobbying on a new issue. Three unrelated kinds of activity within 168 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Short interest and volume: Short interest spike, became public on 10 Aug 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
  • Short interest and volume: Short interest spike, became public on 27 Aug 2024
  • Short interest and volume: Short interest spike, became public on 12 Sep 2024
  • Short interest and volume: Short interest spike, became public on 25 Sep 2024
  • Short interest and volume: Short interest spike, became public on 10 Oct 2024
  • Lobbying: Lobbying on a new issue, became public on 21 Oct 2024
  • Short interest and volume: Short interest spike, became public on 25 Oct 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
  • Short interest and volume: Short interest spike, became public on 13 Nov 2024
  • Short interest and volume: Short interest spike, became public on 27 Nov 2024
  • Short interest and volume: Short interest spike, became public on 11 Dec 2024
  • Short interest and volume: Short interest spike, became public on 25 Dec 2024
  • Short interest and volume: Short interest spike, became public on 14 Jan 2025
2022-06-30: 192022-09-30: 72022-12-31: 102023-03-31: 92023-06-30: 112023-09-30: 142023-12-31: 82024-03-31: 162024-06-30: 40
The quarter ended 30 Jun 2024 against the 8 quarters before it. this quarterearliernormal: 10.5
See the evidence (15 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2024

Humacyte had 14.6M shares sold short in the 15 Jul 2024 report, 4.9× the same report last year.

This period
14.6M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
5.2M
Typical spread (median absolute deviation)
882K
How far from its usual level
+7.2
Same report last year
3.0M
History used
1,049 days
2023-07-14: 3.0M2023-07-31: 3.0M2023-08-15: 3.2M2023-08-31: 3.8M2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M
the 15 Jul 2024 report24 earlier reportsnormal: 5.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Aug 2024

Humacyte had 12.0M shares sold short in the 31 Jul 2024 report, 4.0× the same report last year.

This period
12.0M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
5.3M
Typical spread (median absolute deviation)
818K
How far from its usual level
+5.5
Same report last year
3.0M
History used
1,065 days
2023-07-31: 3.0M2023-08-15: 3.2M2023-08-31: 3.8M2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M
the 31 Jul 2024 report24 earlier reportsnormal: 5.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

Humacyte saw 40 13F filers open a new position in the quarter ended 30 Jun 2024, 3.6× the same quarter last year.

This period
40 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
3
How far from its usual level
+6.6
Same quarter last year
11
History used
1,004 days
2022-06-30: 192022-09-30: 72022-12-31: 102023-03-31: 92023-06-30: 112023-09-30: 142023-12-31: 82024-03-31: 162024-06-30: 40
the quarter ended 30 Jun 20248 earlier quartersnormal: 10.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 27 Aug 2024

Humacyte had 11.4M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.

This period
11.4M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
715K
How far from its usual level
+5.7
Same report last year
3.2M
History used
1,080 days
2023-08-15: 3.2M2023-08-31: 3.8M2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M
the 15 Aug 2024 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Sep 2024

Humacyte had 11.3M shares sold short in the 30 Aug 2024 report, 3.0× the same report last year.

This period
11.3M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
5.5M
Typical spread (median absolute deviation)
608K
How far from its usual level
+6.4
Same report last year
3.8M
History used
1,095 days
2023-08-31: 3.8M2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M
the 30 Aug 2024 report24 earlier reportsnormal: 5.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2024

Humacyte had 14.0M shares sold short in the 13 Sep 2024 report, 2.7× the same report last year.

This period
14.0M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
5.7M
Typical spread (median absolute deviation)
705K
How far from its usual level
+7.9
Same report last year
5.2M
History used
1,109 days
2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M
the 13 Sep 2024 report24 earlier reportsnormal: 5.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Oct 2024

Humacyte had 16.0M shares sold short in the 30 Sep 2024 report, 3.0× the same report last year.

This period
16.0M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
5.9M
Typical spread (median absolute deviation)
900K
How far from its usual level
+7.6
Same report last year
5.3M
History used
1,126 days
2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M
the 30 Sep 2024 report24 earlier reportsnormal: 5.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 21 Oct 2024

Humacyte lobbying on a new issue.

New
['BUD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6275685

Short interest and volume: Short interest spike became public on 25 Oct 2024

Humacyte had 16.7M shares sold short in the 15 Oct 2024 report, 3.3× the same report last year.

This period
16.7M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
6.0M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+5.6
Same report last year
5.1M
History used
1,141 days
2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M
the 15 Oct 2024 report24 earlier reportsnormal: 6.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

Humacyte saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.

This period
32 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
3
How far from its usual level
+4.8
Same quarter last year
14
History used
1,096 days
2022-09-30: 72022-12-31: 102023-03-31: 92023-06-30: 112023-09-30: 142023-12-31: 82024-03-31: 162024-06-30: 402024-09-30: 32
the quarter ended 30 Sep 20248 earlier quartersnormal: 10.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 13 Nov 2024

Humacyte had 17.3M shares sold short in the 31 Oct 2024 report, 3.1× the same report last year.

This period
17.3M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
6.1M
Typical spread (median absolute deviation)
1.7M
How far from its usual level
+4.4
Same report last year
5.5M
History used
1,157 days
2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M
the 31 Oct 2024 report24 earlier reportsnormal: 6.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Nov 2024

Humacyte had 19.1M shares sold short in the 15 Nov 2024 report, 3.1× the same report last year.

This period
19.1M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
6.1M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+4.3
Same report last year
6.1M
History used
1,172 days
2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M
the 15 Nov 2024 report24 earlier reportsnormal: 6.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Dec 2024

Humacyte had 20.3M shares sold short in the 29 Nov 2024 report, 3.5× the same report last year.

This period
20.3M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
6.1M
Typical spread (median absolute deviation)
2.1M
How far from its usual level
+4.5
Same report last year
5.9M
History used
1,186 days
2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M2024-11-29: 20.3M
the 29 Nov 2024 report24 earlier reportsnormal: 6.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Dec 2024

Humacyte had 22.0M shares sold short in the 13 Dec 2024 report, 3.9× the same report last year.

This period
22.0M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
6.3M
Typical spread (median absolute deviation)
2.4M
How far from its usual level
+4.4
Same report last year
5.6M
History used
1,200 days
2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M2024-11-29: 20.3M2024-12-13: 22.0M
the 13 Dec 2024 report24 earlier reportsnormal: 6.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 14 Jan 2025

Humacyte had 29.6M shares sold short in the 31 Dec 2024 report, 4.9× the same report last year.

This period
29.6M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
7.4M
Typical spread (median absolute deviation)
3.5M
How far from its usual level
+4.2
Same report last year
6.0M
History used
1,218 days
2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M2024-11-29: 20.3M2024-12-13: 22.0M2024-12-31: 29.6M
the 31 Dec 2024 report24 earlier reportsnormal: 7.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 28 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 28 Sep 2026Filings record

    Director or officer change

  3. 16 Sep 2026Insiders record

    Jones Keith Anthony (director) bought 10,000 shares of HUMA ($5,600) (dated 15 Sep 2026)

  4. 22 Aug 2026Insiders record

    Jones Keith Anthony (director) bought 10,000 shares of HUMA ($6,900) (dated 21 Aug 2026)

  5. 20 Aug 2026Insiders record

    Jones Keith Anthony (director) bought 30,000 shares of HUMA ($17,700) (dated 19 Aug 2026)

  6. 31 Jul 2026Filings record

    Delisting notice or listing transfer

  7. 21 May 2026Insiders record

    Sebelius Kathleen (director) bought 56,818 shares of HUMA ($50,000) (dated 20 May 2026)

  8. 21 May 2026Insiders record

    Constantino Michael T. (director) bought 11,000 shares of HUMA ($9,790) (dated 20 May 2026)

  9. 8 May 2026Filings record

    Delisting notice or listing transfer

  10. 15 Dec 2025Filings record

    A major agreement ended

  11. 26 Nov 2025Filings record

    A major agreement ended

  12. 20 Oct 2025Lobbying record

    HUMACYTE: new lobbying registration (CAPITOL HILL CONSULTING GROUP) (dated 15 Jul 2025)

  13. 15 Oct 2025Lobbying record

    HUMACYTE: lobbying engagement terminated (G2G CONSULTING) (dated 31 Aug 2025)

  14. 21 Apr 2025Lobbying record

    HUMACYTE, INC.: lobbying engagement terminated (DLA PIPER LLP (US)) (dated 1 Jan 2025)

  15. 16 Apr 2025Insiders record

    Scheessele William John (Chief Commercial Officer) bought 6,493 shares of HUMA ($9,999) (dated 15 Apr 2025)

  16. 15 Apr 2025Insiders change

    had 5 insiders buy $136K of its shares on the open market within 30 days (5 filings).

    Who bought: Constantino Michael T., Green Charles Bruce, Sebelius Kathleen, Sander Dale A. and 1 more.

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $136K
    Window
    16 Mar 2025 to 15 Apr 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  17. 15 Apr 2025Insiders record

    Parikh Shamik J (Chief Medical Officer) bought 7,500 shares of HUMA ($11,625) (dated 14 Apr 2025)

  18. 15 Apr 2025Insiders record

    Sander Dale A. (CFO and Chief Corp. Deve. Off.) bought 20,000 shares of HUMA ($30,600) (dated 14 Apr 2025)

  19. 9 Apr 2025Insiders record

    Sebelius Kathleen (director) bought 50,000 shares of HUMA ($66,000) (dated 8 Apr 2025)

  20. 9 Apr 2025Insiders record

    Green Charles Bruce (director) bought 6,000 shares of HUMA ($7,740) (dated 8 Apr 2025)

  21. 9 Apr 2025Insiders record

    Constantino Michael T. (director) bought 16,000 shares of HUMA ($20,160) (dated 8 Apr 2025)

  22. 14 Feb 2025Institutional holdings change

    saw 34 13F filers open a new position in the quarter ended 31 Dec 2024, 4.2× the same quarter last year.

    Same quarter last year: 8; its normal quarter is 12.5.

    See the evidence
    This period
    34 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    12.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.1
    Same quarter last year
    8
    History used
    1,188 days
    2022-12-31: 102023-03-31: 92023-06-30: 112023-09-30: 142023-12-31: 82024-03-31: 162024-06-30: 402024-09-30: 322024-12-31: 34
    the quarter ended 31 Dec 20248 earlier quartersnormal: 12.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 14 Jan 2025Short interest and volume change

    had 29.6M shares sold short in the 31 Dec 2024 report, 4.9× the same report last year.

    Same report last year: 6.0M; its normal report is 7.4M.

    See the evidence
    This period
    29.6M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    7.4M
    Typical spread (median absolute deviation)
    3.5M
    How far from its usual level
    +4.2
    Same report last year
    6.0M
    History used
    1,218 days
    2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M2024-11-29: 20.3M2024-12-13: 22.0M2024-12-31: 29.6M
    the 31 Dec 2024 report24 earlier reportsnormal: 7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 Dec 2024Short interest and volume change

    had 22.0M shares sold short in the 13 Dec 2024 report, 3.9× the same report last year.

    Same report last year: 5.6M; its normal report is 6.3M.

    See the evidence
    This period
    22.0M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    2.4M
    How far from its usual level
    +4.4
    Same report last year
    5.6M
    History used
    1,200 days
    2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M2024-11-29: 20.3M2024-12-13: 22.0M
    the 13 Dec 2024 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 11 Dec 2024Short interest and volume change

    had 20.3M shares sold short in the 29 Nov 2024 report, 3.5× the same report last year.

    Same report last year: 5.9M; its normal report is 6.1M.

    See the evidence
    This period
    20.3M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    2.1M
    How far from its usual level
    +4.5
    Same report last year
    5.9M
    History used
    1,186 days
    2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M2024-11-29: 20.3M
    the 29 Nov 2024 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 5 Dec 2024Insiders record

    Constantino Michael T. (director) bought 4,600 shares of HUMA ($20,194) (dated 4 Dec 2024)

  27. 27 Nov 2024Short interest and volume change

    had 19.1M shares sold short in the 15 Nov 2024 report, 3.1× the same report last year.

    Same report last year: 6.1M; its normal report is 6.1M.

    See the evidence
    This period
    19.1M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +4.3
    Same report last year
    6.1M
    History used
    1,172 days
    2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M2024-11-15: 19.1M
    the 15 Nov 2024 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 22 Nov 2024Insiders record

    Dougan Brady W (director) bought 1,797 shares of HUMA ($7,979) (dated 21 Nov 2024)

  29. 22 Nov 2024Insiders record

    Niklason Laura E (President, CEO and Director) bought 1,797 shares of HUMA ($7,979) (dated 21 Nov 2024)

  30. 14 Nov 2024Institutional holdings change

    saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.

    Same quarter last year: 14; its normal quarter is 10.5.

    See the evidence
    This period
    32 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +4.8
    Same quarter last year
    14
    History used
    1,096 days
    2022-09-30: 72022-12-31: 102023-03-31: 92023-06-30: 112023-09-30: 142023-12-31: 82024-03-31: 162024-06-30: 402024-09-30: 32
    the quarter ended 30 Sep 20248 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  31. 13 Nov 2024Short interest and volume change

    had 17.3M shares sold short in the 31 Oct 2024 report, 3.1× the same report last year.

    Same report last year: 5.5M; its normal report is 6.1M.

    See the evidence
    This period
    17.3M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    1.7M
    How far from its usual level
    +4.4
    Same report last year
    5.5M
    History used
    1,157 days
    2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M2024-10-31: 17.3M
    the 31 Oct 2024 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 25 Oct 2024Short interest and volume change

    had 16.7M shares sold short in the 15 Oct 2024 report, 3.3× the same report last year.

    Same report last year: 5.1M; its normal report is 6.0M.

    See the evidence
    This period
    16.7M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    6.0M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +5.6
    Same report last year
    5.1M
    History used
    1,141 days
    2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M2024-10-15: 16.7M
    the 15 Oct 2024 report24 earlier reportsnormal: 6.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 21 Oct 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['BUD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6275685
  34. 10 Oct 2024Short interest and volume change

    had 16.0M shares sold short in the 30 Sep 2024 report, 3.0× the same report last year.

    Same report last year: 5.3M; its normal report is 5.9M.

    See the evidence
    This period
    16.0M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    5.9M
    Typical spread (median absolute deviation)
    900K
    How far from its usual level
    +7.6
    Same report last year
    5.3M
    History used
    1,126 days
    2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M2024-09-30: 16.0M
    the 30 Sep 2024 report24 earlier reportsnormal: 5.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 26 Sep 2024Lobbying record

    HUMACYTE, INC.: new lobbying registration (DLA PIPER LLP (US)) (dated 1 Sep 2024)

  36. 25 Sep 2024Short interest and volume change

    had 14.0M shares sold short in the 13 Sep 2024 report, 2.7× the same report last year.

    Same report last year: 5.2M; its normal report is 5.7M.

    See the evidence
    This period
    14.0M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    705K
    How far from its usual level
    +7.9
    Same report last year
    5.2M
    History used
    1,109 days
    2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M2024-09-13: 14.0M
    the 13 Sep 2024 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 12 Sep 2024Short interest and volume change

    had 11.3M shares sold short in the 30 Aug 2024 report, 3.0× the same report last year.

    Same report last year: 3.8M; its normal report is 5.5M.

    See the evidence
    This period
    11.3M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    5.5M
    Typical spread (median absolute deviation)
    608K
    How far from its usual level
    +6.4
    Same report last year
    3.8M
    History used
    1,095 days
    2023-08-31: 3.8M2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M2024-08-30: 11.3M
    the 30 Aug 2024 report24 earlier reportsnormal: 5.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 4 Sep 2024Insiders record

    Dougan Brady W (director) bought 1,222 shares of HUMA ($8,004) (dated 3 Sep 2024)

  39. 4 Sep 2024Insiders record

    Niklason Laura E (President, CEO and Director) bought 1,222 shares of HUMA ($8,004) (dated 3 Sep 2024)

  40. 27 Aug 2024Short interest and volume change

    had 11.4M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.

    Same report last year: 3.2M; its normal report is 5.4M.

    See the evidence
    This period
    11.4M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    5.4M
    Typical spread (median absolute deviation)
    715K
    How far from its usual level
    +5.7
    Same report last year
    3.2M
    History used
    1,080 days
    2023-08-15: 3.2M2023-08-31: 3.8M2023-09-15: 5.2M2023-09-29: 5.3M2023-10-13: 5.1M2023-10-31: 5.5M2023-11-15: 6.1M2023-11-30: 5.9M2023-12-15: 5.6M2023-12-29: 6.0M2024-01-12: 6.1M2024-01-31: 6.1M2024-02-15: 6.6M2024-02-29: 6.0M2024-03-15: 3.8M2024-03-28: 4.0M2024-04-15: 3.9M2024-04-30: 4.5M2024-05-15: 4.2M2024-05-31: 4.9M2024-06-14: 5.2M2024-06-28: 8.2M2024-07-15: 14.6M2024-07-31: 12.0M2024-08-15: 11.4M
    the 15 Aug 2024 report24 earlier reportsnormal: 5.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.

Not listed: 134 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001818382
Ticker
HUMA
Domain
humacyte.com
Employer name
humacyte global (1 unverified)
Hq location
NC|DURHAM|27713 (1 unverified)
Lobbying client
humacyte
Name
Alpha Healthcare Acquisition Corp., EX-21.1, Humacyte Europe Limited, Humacyte Global, Inc and 2 more
Uei
XRKCWCMCZKE7
  • Federal lobbying disclosures (LDA)13 records, 142 data points28 Nov 2011 to 30 Sep 2026
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)109 records4 Aug 2020 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)369 data points31 Dec 2019 to 10 Nov 2026
  • SEC Form 4 insider transactions84 records, 148 data points27 Aug 2021 to 15 Sep 2026
  • FINRA short interest (twice monthly)372 data points31 Aug 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2630 data points27 Aug 2021 to 20 Nov 2026